Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1

被引：84

作者：

Roth, Patrick

Mittelbronn, Michel

Wick, Wolfgang

Meyermann, Richard

Tatagiba, Marcos

Weller, Michael

机构：

[1] Univ Tubingen, Dept Gen Neurobiol, Hertie Inst Clin Brain Res, Lab Mol Neurooncol, D-72076 Tubingen, Germany

[2] Univ Tubingen, Inst Brain Res, D-72076 Tubingen, Germany

[3] Univ Tubingen, Dept Neurosurg, D-72076 Tubingen, Germany

来源：

CANCER RESEARCH | 2007年 / 67卷 / 08期

关键词：

D O I：

10.1158/0008-5472.CAN-06-4783

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Glioblastoma, one of the most lethal tumors, is paradigmatic for tumor-associated immunosuppression. Lectin-like transcript-1 (LLT1) is a newly identified ligand for the inhibitory natural killer (NK) cell receptor CD161. Here, we report that glioma cells express LLT1 mRNA and protein in vitro and in vivo, whereas expression levels in normal brain are low. LLT1 expression in human gliomas increases with the WHO grade of malignancy. We further show that transforming growth factor-beta (TGF-beta) up-regulates the expression of LLT1 in glioma cells. Small interfering RNA (siRNA)-mediated down-regulation of LLT1 in LNT-229 and LN-428 cells promotes their lysis by NK cells. Thus, LLT1 acts as a mediator of immune escape and contributes to the immunosuppressive properties of glioma cells.

引用

页码：3540 / 3544

页数：5